Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas

Justin S. Smith, Arie Perry, Thomas J. Borell, Hyun K. Lee, Judith O'Fallon, Sandra M. Hosek, David Kimmel, Allan Yates, Peter C. Burger, Bernd W. Scheithauer, Robert Brian Jenkins

Research output: Contribution to journalArticle

675 Citations (Scopus)

Abstract

Purpose: A recent report suggests that alterations of chromosome arms 1 p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. Patients and Methods: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. Results: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log- rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma. Conclusion: Combined loss of 1 p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)636-645
Number of pages10
JournalJournal of Clinical Oncology
Volume18
Issue number3
StatePublished - Feb 2000

Fingerprint

Oligodendroglioma
Astrocytoma
Chromosomes
Survival
Neoplasms
Lomustine
Procarbazine
Chromosomes, Human, Pair 1
DNA Probes
Vincristine
Fluorescence In Situ Hybridization
Glioma
Phenotype
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. / Smith, Justin S.; Perry, Arie; Borell, Thomas J.; Lee, Hyun K.; O'Fallon, Judith; Hosek, Sandra M.; Kimmel, David; Yates, Allan; Burger, Peter C.; Scheithauer, Bernd W.; Jenkins, Robert Brian.

In: Journal of Clinical Oncology, Vol. 18, No. 3, 02.2000, p. 636-645.

Research output: Contribution to journalArticle

Smith, JS, Perry, A, Borell, TJ, Lee, HK, O'Fallon, J, Hosek, SM, Kimmel, D, Yates, A, Burger, PC, Scheithauer, BW & Jenkins, RB 2000, 'Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas', Journal of Clinical Oncology, vol. 18, no. 3, pp. 636-645.
Smith, Justin S. ; Perry, Arie ; Borell, Thomas J. ; Lee, Hyun K. ; O'Fallon, Judith ; Hosek, Sandra M. ; Kimmel, David ; Yates, Allan ; Burger, Peter C. ; Scheithauer, Bernd W. ; Jenkins, Robert Brian. / Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 3. pp. 636-645.
@article{7c57564ce5fd42cd802fd70127f41e8c,
title = "Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas",
abstract = "Purpose: A recent report suggests that alterations of chromosome arms 1 p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. Patients and Methods: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. Results: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log- rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma. Conclusion: Combined loss of 1 p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management. (C) 2000 by American Society of Clinical Oncology.",
author = "Smith, {Justin S.} and Arie Perry and Borell, {Thomas J.} and Lee, {Hyun K.} and Judith O'Fallon and Hosek, {Sandra M.} and David Kimmel and Allan Yates and Burger, {Peter C.} and Scheithauer, {Bernd W.} and Jenkins, {Robert Brian}",
year = "2000",
month = "2",
language = "English (US)",
volume = "18",
pages = "636--645",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas

AU - Smith, Justin S.

AU - Perry, Arie

AU - Borell, Thomas J.

AU - Lee, Hyun K.

AU - O'Fallon, Judith

AU - Hosek, Sandra M.

AU - Kimmel, David

AU - Yates, Allan

AU - Burger, Peter C.

AU - Scheithauer, Bernd W.

AU - Jenkins, Robert Brian

PY - 2000/2

Y1 - 2000/2

N2 - Purpose: A recent report suggests that alterations of chromosome arms 1 p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. Patients and Methods: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. Results: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log- rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma. Conclusion: Combined loss of 1 p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: A recent report suggests that alterations of chromosome arms 1 p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. Patients and Methods: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. Results: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log- rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma. Conclusion: Combined loss of 1 p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0033951824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033951824&partnerID=8YFLogxK

M3 - Article

C2 - 10653879

AN - SCOPUS:0033951824

VL - 18

SP - 636

EP - 645

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -